Proteostasis Therapeutics, Inc. (NASDAQ:PTI) increased to $4.17. It was reported on Mar, 13 by Barchart.com. It has $204.75M market cap. At $4.33 stock PT, the company valuation changes by $8.19 million more.

For more Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news published briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Health Care Sector Update for 12/17/2018: PTI, EVFM, BCLI, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on December 17, 2018, “Vertex’s VX-445 Triple Combo Cystic Fibrosis Trials Succeed – Nasdaq” on March 07, 2019, “FDA Nod For GNMK, AKRX Gets New CEO, PTI Plunges After-hours – Nasdaq” with a publish date: December 20, 2018, “Pre-Market Most Active for Dec 17, 2018 : TAL, PTI, AMD, QQQ, LYG, NOK, SQQQ, BHP, VOD, TVIX, CHK, SNY – Nasdaq” and the last “Uniti Group Inc. Agrees to Sale of Latin America Tower Portfolio – GlobeNewswire” with publication date: February 19, 2019.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis.The firm is valued at $204.75 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies.Last it reported negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.